---
created: 2025-04-13
updated: 2025-04-13T10:52
id: Mbv69w87QN
specialty: endo
specialty_id: 74
tags:
  - source/ak-original-decks::step-1::zanki-pharmacology
  - "source/ak-step1-v11:": 
  - theme/b&b::14-msk::03-pathology::01-bone-disorders
  - "source/ak-step1-v11:": 
  - theme/firstaid::11-musculoskeletal-skin-connective-tissue::04-pharm::07-bisphosphonates
  - "source/ak-step1-v11:": 
  - source/ome-banner::basic-science::10-musculoskeletal
  - "source/ak-step1-v11:": 
  - theme/physeo::09-pharm::09-musculoskeletal::06-bisphosphonates
  - "source/ak-step1-v11:": 
  - theme/pixorize::03-pharm::12-msk::bisphosphonates
  - "source/ak-step1-v11:": 
  - theme/sketchypharm::05-gi-&-endocrine::03-thyroid,-parathyroid-&-adrenal::02-bisphosphonates,-raloxifene,-denosumab,-calcitonin
  - source/ak-step1-v11::^other::^highyield::1-highyield
  - source/ak-step1-v11::^systems::endocrine::pharmacology"
type: flashcard
---

# Question
**Bisphosphonates** and **calcitonin** are useful in the management of **Paget disease**, which is characterized by uncontrolled osteoclast resorption with secondary disorganized bone formation

---

# Answer
look for isolated ALP increase in Paget